Finally, while growing evidence demonstrates that a pharmacological block of the JAK-STAT pathway could effectively treat nephropathy, for decades, the first-line treatment for obesity-related glomerulopathy has been RAS inhibitors (Jiang et al., 2023). This evidence concerns the gene SOAT1 and lipoprotein glomerulopathy.